APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Fibrosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Kidney Fibrosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025180 pages

Choose your research edition.

Industry ResearchKidney Fibrosis Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Fibrosis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Kidney Fibrosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Fibrosis Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Fibrosis Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Kidney Fibrosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Kidney Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Kidney Fibrosis Drugs include Merck and Co, F. Hoffman-La Roche, Pfizer Inc, ProMetic Life-Sciences Inc, La Jolla Pharmaceutical Company, InterMune Inc, Genzyme Corporation, Galectin Therapeutics and BioLine Rx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Kidney Fibrosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Kidney Fibrosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Kidney Fibrosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Kidney Fibrosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Kidney Fibrosis Drugs Segment by Company

Merck and Co

F. Hoffman-La Roche

Pfizer Inc

ProMetic Life-Sciences Inc

La Jolla Pharmaceutical Company

InterMune Inc

Genzyme Corporation

Galectin Therapeutics

BioLine Rx

Kidney Fibrosis Drugs Segment by Type

Angiotensin Converting Enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Renin Inhibitors

Vasopeptidase Inhibitors

Pirfenidone

Kidney Fibrosis Drugs Segment by Application

Chronic Kidney Diseases

Kidney Cancer Treatment

Others

Kidney Fibrosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Fibrosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Fibrosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Fibrosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Kidney Fibrosis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Kidney Fibrosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Kidney Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Kidney Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Kidney Fibrosis Drugs Industry Trends Table 2. Kidney Fibrosis Drugs Industry Drivers Table 3. Kidney Fibrosis Drugs Industry Opportunities and Challenges Table 4. Kidney Fibrosis Drugs Industry Restraints Table 5. Global Kidney Fibrosis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Kidney Fibrosis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Kidney Fibrosis Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Kidney Fibrosis Drugs Sales Market Share by Manufacturers Table 9. Global Kidney Fibrosis Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Kidney Fibrosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Kidney Fibrosis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Kidney Fibrosis Drugs Manufacturers, Product Type & Application Table 13. Global Kidney Fibrosis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Kidney Fibrosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors Table 17. Major Manufacturers of Angiotensin II Receptor Blockers (ARBs) Table 18. Major Manufacturers of Renin Inhibitors Table 19. Major Manufacturers of Vasopeptidase Inhibitors Table 20. Major Manufacturers of Pirfenidone Table 21. Global Kidney Fibrosis Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Kidney Fibrosis Drugs Sales by Type (2021-2026) & (k units) Table 23. Global Kidney Fibrosis Drugs Sales by Type (2027-2032) & (k units) Table 24. Global Kidney Fibrosis Drugs Sales Market Share by Type (2021-2026) Table 25. Global Kidney Fibrosis Drugs Sales Market Share by Type (2027-2032) Table 26. Global Kidney Fibrosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Kidney Fibrosis Drugs Revenue by Type (2021-2026) & (k units) Table 28. Global Kidney Fibrosis Drugs Revenue by Type (2027-2032) & (k units) Table 29. Global Kidney Fibrosis Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Kidney Fibrosis Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Chronic Kidney Diseases Table 32. Major Manufacturers of Kidney Cancer Treatment Table 33. Major Manufacturers of Others Table 34. Global Kidney Fibrosis Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Kidney Fibrosis Drugs Sales by Application (2021-2026) & (k units) Table 36. Global Kidney Fibrosis Drugs Sales by Application (2027-2032) & (k units) Table 37. Global Kidney Fibrosis Drugs Sales Market Share by Application (2021-2026) Table 38. Global Kidney Fibrosis Drugs Sales Market Share by Application (2027-2032) Table 39. Global Kidney Fibrosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Kidney Fibrosis Drugs Revenue by Application (2021-2026) & (k units) Table 41. Global Kidney Fibrosis Drugs Revenue by Application (2027-2032) & (k units) Table 42. Global Kidney Fibrosis Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Kidney Fibrosis Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Kidney Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Kidney Fibrosis Drugs Sales by Region (2021-2026) & (k units) Table 46. Global Kidney Fibrosis Drugs Sales Market Share by Region (2021-2026) Table 47. Global Kidney Fibrosis Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Kidney Fibrosis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 51. North America Kidney Fibrosis Drugs Sales by Country (2027-2032) & (k units) Table 52. Europe Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 54. Europe Kidney Fibrosis Drugs Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Kidney Fibrosis Drugs Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Kidney Fibrosis Drugs Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Kidney Fibrosis Drugs Sales by Country (2027-2032) & (k units) Table 61. Global Kidney Fibrosis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Kidney Fibrosis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Kidney Fibrosis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Kidney Fibrosis Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Kidney Fibrosis Drugs Revenue Market Share by Region (2027-2032) Table 66. Merck and Co Company Information Table 67. Merck and Co Business Overview Table 68. Merck and Co Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck and Co Kidney Fibrosis Drugs Product Portfolio Table 70. Merck and Co Recent Development Table 71. F. Hoffman-La Roche Company Information Table 72. F. Hoffman-La Roche Business Overview Table 73. F. Hoffman-La Roche Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolio Table 75. F. Hoffman-La Roche Recent Development Table 76. Pfizer Inc Company Information Table 77. Pfizer Inc Business Overview Table 78. Pfizer Inc Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Pfizer Inc Kidney Fibrosis Drugs Product Portfolio Table 80. Pfizer Inc Recent Development Table 81. ProMetic Life-Sciences Inc Company Information Table 82. ProMetic Life-Sciences Inc Business Overview Table 83. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolio Table 85. ProMetic Life-Sciences Inc Recent Development Table 86. La Jolla Pharmaceutical Company Company Information Table 87. La Jolla Pharmaceutical Company Business Overview Table 88. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolio Table 90. La Jolla Pharmaceutical Company Recent Development Table 91. InterMune Inc Company Information Table 92. InterMune Inc Business Overview Table 93. InterMune Inc Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. InterMune Inc Kidney Fibrosis Drugs Product Portfolio Table 95. InterMune Inc Recent Development Table 96. Genzyme Corporation Company Information Table 97. Genzyme Corporation Business Overview Table 98. Genzyme Corporation Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Genzyme Corporation Kidney Fibrosis Drugs Product Portfolio Table 100. Genzyme Corporation Recent Development Table 101. Galectin Therapeutics Company Information Table 102. Galectin Therapeutics Business Overview Table 103. Galectin Therapeutics Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolio Table 105. Galectin Therapeutics Recent Development Table 106. BioLine Rx Company Information Table 107. BioLine Rx Business Overview Table 108. BioLine Rx Kidney Fibrosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. BioLine Rx Kidney Fibrosis Drugs Product Portfolio Table 110. BioLine Rx Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Kidney Fibrosis Drugs Distributors List Table 114. Kidney Fibrosis Drugs Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Kidney Fibrosis Drugs Product Image Figure 2. Global Kidney Fibrosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Fibrosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Kidney Fibrosis Drugs Sales (2021-2032) & (k units) Figure 5. Global Kidney Fibrosis Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Kidney Fibrosis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Angiotensin Converting Enzyme (ACE) Inhibitors Image Figure 9. Angiotensin II Receptor Blockers (ARBs) Image Figure 10. Renin Inhibitors Image Figure 11. Vasopeptidase Inhibitors Image Figure 12. Pirfenidone Image Figure 13. Global Kidney Fibrosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Kidney Fibrosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Kidney Fibrosis Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Kidney Fibrosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Kidney Fibrosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Kidney Fibrosis Drugs Revenue Market Share by Type (2021-2032) Figure 19. Chronic Kidney Diseases Image Figure 20. Kidney Cancer Treatment Image Figure 21. Others Image Figure 22. Global Kidney Fibrosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Kidney Fibrosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Kidney Fibrosis Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Kidney Fibrosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Kidney Fibrosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Kidney Fibrosis Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Kidney Fibrosis Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Kidney Fibrosis Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Kidney Fibrosis Drugs Sales Market Share by Country (2021-2032) Figure 42. China Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Kidney Fibrosis Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Kidney Fibrosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Kidney Fibrosis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Kidney Fibrosis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Kidney Fibrosis Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Kidney Fibrosis Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Kidney Fibrosis Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Kidney Fibrosis Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Kidney Fibrosis Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Kidney Fibrosis Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Renin Inhibitors
  • Vasopeptidase Inhibitors
  • Pirfenidone
Applications
  • Chronic Kidney Diseases
  • Kidney Cancer Treatment
  • Others
Companies covered
  • Merck and Co
  • F. Hoffman-La Roche
  • Pfizer Inc
  • ProMetic Life-Sciences Inc
  • La Jolla Pharmaceutical Company
  • InterMune Inc
  • Genzyme Corporation
  • Galectin Therapeutics
  • BioLine Rx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Kidney Fibrosis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Kidney Fibrosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Kidney Fibrosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Kidney Fibrosis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Kidney Fibrosis Drugs Market Dynamics
  1. 2.1 Kidney Fibrosis Drugs Industry Trends
  2. 2.2 Kidney Fibrosis Drugs Industry Drivers
  3. 2.3 Kidney Fibrosis Drugs Industry Opportunities and Challenges
  4. 2.4 Kidney Fibrosis Drugs Industry Restraints
3 Kidney Fibrosis Drugs Market by Manufacturers
  1. 3.1 Global Kidney Fibrosis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Kidney Fibrosis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Kidney Fibrosis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Kidney Fibrosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Kidney Fibrosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Kidney Fibrosis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Kidney Fibrosis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Kidney Fibrosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Kidney Fibrosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Kidney Fibrosis Drugs Tier 1, Tier 2, and Tier 3
4 Kidney Fibrosis Drugs Market by Type
  1. 4.1 Kidney Fibrosis Drugs Type Introduction
  2. 4.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors
  3. 4.1.2 Angiotensin II Receptor Blockers (ARBs)
  4. 4.1.3 Renin Inhibitors
  5. 4.1.4 Vasopeptidase Inhibitors
  6. 4.1.5 Pirfenidone
  7. 4.2 Global Kidney Fibrosis Drugs Sales by Type
  8. 4.2.1 Global Kidney Fibrosis Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Kidney Fibrosis Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Kidney Fibrosis Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Kidney Fibrosis Drugs Revenue by Type
  12. 4.3.1 Global Kidney Fibrosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Kidney Fibrosis Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Kidney Fibrosis Drugs Revenue Market Share by Type (2021-2032)
5 Kidney Fibrosis Drugs Market by Application
  1. 5.1 Kidney Fibrosis Drugs Application Introduction
  2. 5.1.1 Chronic Kidney Diseases
  3. 5.1.2 Kidney Cancer Treatment
  4. 5.1.3 Others
  5. 5.2 Global Kidney Fibrosis Drugs Sales by Application
  6. 5.2.1 Global Kidney Fibrosis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Kidney Fibrosis Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Kidney Fibrosis Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Kidney Fibrosis Drugs Revenue by Application
  10. 5.3.1 Global Kidney Fibrosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Kidney Fibrosis Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Kidney Fibrosis Drugs Revenue Market Share by Application (2021-2032)
6 Global Kidney Fibrosis Drugs Sales by Region
  1. 6.1 Global Kidney Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Kidney Fibrosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Kidney Fibrosis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Kidney Fibrosis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Kidney Fibrosis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Kidney Fibrosis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Kidney Fibrosis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Kidney Fibrosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Kidney Fibrosis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Kidney Fibrosis Drugs Revenue by Region
  1. 7.1 Global Kidney Fibrosis Drugs Revenue by Region
  2. 7.1.1 Global Kidney Fibrosis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Kidney Fibrosis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Kidney Fibrosis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Kidney Fibrosis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Kidney Fibrosis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Kidney Fibrosis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Kidney Fibrosis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Kidney Fibrosis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Kidney Fibrosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck and Co
  2. 8.1.1 Merck and Co Company Information
  3. 8.1.2 Merck and Co Business Overview
  4. 8.1.3 Merck and Co Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck and Co Kidney Fibrosis Drugs Product Portfolio
  6. 8.1.5 Merck and Co Recent Developments
  7. 8.2 F. Hoffman-La Roche
  8. 8.2.1 F. Hoffman-La Roche Company Information
  9. 8.2.2 F. Hoffman-La Roche Business Overview
  10. 8.2.3 F. Hoffman-La Roche Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolio
  12. 8.2.5 F. Hoffman-La Roche Recent Developments
  13. 8.3 Pfizer Inc
  14. 8.3.1 Pfizer Inc Company Information
  15. 8.3.2 Pfizer Inc Business Overview
  16. 8.3.3 Pfizer Inc Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc Kidney Fibrosis Drugs Product Portfolio
  18. 8.3.5 Pfizer Inc Recent Developments
  19. 8.4 ProMetic Life-Sciences Inc
  20. 8.4.1 ProMetic Life-Sciences Inc Company Information
  21. 8.4.2 ProMetic Life-Sciences Inc Business Overview
  22. 8.4.3 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolio
  24. 8.4.5 ProMetic Life-Sciences Inc Recent Developments
  25. 8.5 La Jolla Pharmaceutical Company
  26. 8.5.1 La Jolla Pharmaceutical Company Company Information
  27. 8.5.2 La Jolla Pharmaceutical Company Business Overview
  28. 8.5.3 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolio
  30. 8.5.5 La Jolla Pharmaceutical Company Recent Developments
  31. 8.6 InterMune Inc
  32. 8.6.1 InterMune Inc Company Information
  33. 8.6.2 InterMune Inc Business Overview
  34. 8.6.3 InterMune Inc Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 InterMune Inc Kidney Fibrosis Drugs Product Portfolio
  36. 8.6.5 InterMune Inc Recent Developments
  37. 8.7 Genzyme Corporation
  38. 8.7.1 Genzyme Corporation Company Information
  39. 8.7.2 Genzyme Corporation Business Overview
  40. 8.7.3 Genzyme Corporation Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genzyme Corporation Kidney Fibrosis Drugs Product Portfolio
  42. 8.7.5 Genzyme Corporation Recent Developments
  43. 8.8 Galectin Therapeutics
  44. 8.8.1 Galectin Therapeutics Company Information
  45. 8.8.2 Galectin Therapeutics Business Overview
  46. 8.8.3 Galectin Therapeutics Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolio
  48. 8.8.5 Galectin Therapeutics Recent Developments
  49. 8.9 BioLine Rx
  50. 8.9.1 BioLine Rx Company Information
  51. 8.9.2 BioLine Rx Business Overview
  52. 8.9.3 BioLine Rx Kidney Fibrosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioLine Rx Kidney Fibrosis Drugs Product Portfolio
  54. 8.9.5 BioLine Rx Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Kidney Fibrosis Drugs Value Chain Analysis
  2. 9.1.1 Kidney Fibrosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Kidney Fibrosis Drugs Production Mode & Process
  6. 9.2 Kidney Fibrosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Kidney Fibrosis Drugs Distributors
  9. 9.2.3 Kidney Fibrosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst